Speaker Profile

M.D., Medical Director Thoracic Oncology, Sutter Health

Dr. Behl specializes in lung cancer, melanoma and head and neck cancers. Dr. Behl leads clinical research and has coauthored peer-reviewed articles and published in high-impact journals such as the Journal of Clinical Oncology (JCO) and Chest.

Emerging Therapeutics Showcase:
Sutter Health

Not Just Any EGFR Mutation: The Importance of Testing for Exon 20
Patients with metastatic NSCLC with EGFR exon 20 insertion mutations have poorer outcomes than those patients who have more common EGFR mutations. Because >100 different EGFR exon 20 insertion mutations have been identified, comprehensive biomarker testing by NGS is recommended

 Session Abstract – PMWC 2022 Silicon Valley

Track 7, June 28-30

The PMWC 2022 Emerging Therapeutics Showcase will provide a 15-minute time slot for selected companies and researchers in the CRISPR, Cell and Gene Therapy fields. Major advancements in safer cell- and gene-level editing technologies are bringing us closer toward cures for life-threatening disorders, from cancer to HIV to Huntington’s disease. Cell therapy, in which cellular material such as T cells capable of fighting cancer cells, is injected into a patient, has been demonstrated safe and effective. The popular new CRISPR tool that has been used to edit the genetic code of nearly any organism will have an enormous impact on human health. More than a dozen clinical trials employing CRISPR on human cells are already underway.

- Emerging Therapeutics/Cell Therapy
- Emerging Therapeutics/CVD
- Emerging Therapeutics/Gene Therapy
- Emerging Therapeutics/Immunotherapy
- Emerging Therapeutics/Radiation Therapy